Clinical Trials Logo

Splenic Marginal Zone Lymphoma clinical trials

View clinical trials related to Splenic Marginal Zone Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05735834 Not yet recruiting - Clinical trials for Splenic Marginal Zone Lymphoma

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

RITZ
Start date: February 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare the efficacy and tolerability of the combination of two medicinal products, rituximab, and zanubrutinib, compared to rituximab monotherapy in patients with Splenic Marginal Zone Lymphoma (SMZL), previously untreated and who need systemic treatment. The main questions it aims to answer are: - Is the combination rituximab and zanubrutinib a more effective therapy than rituximab monotherapy? - Is the combination therapy, rituximab and zanubrutinib, well tolerated? Study participants will be put into one of the two treatment groups (rituximab and zanubrutinib or rituximab alone) for a maximum of two years and will undergo regular visits until three years from treatment start.